echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Express creates multiple firsts!

    Express creates multiple firsts!

    • Last Update: 2022-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Caribou Biosciences announced that its CRISPR-based gene editing-engineered ready-to-use CAR-T therapy CB-010 has achieved positive results in a Phase 1 clinical trial in patients with relapsed/refractory B-cell non-Hodgkin lympho.


    100% overall response rate and 80% complete response rate among 5 patients receiving initial dose of CRISPR gene-edited ready-to-use CAR-T therapy CB-010 CB-010 is the first to achieve 100% overall response rate Allogeneic CAR-T therapy is also the first clinical-stage allogeneic CAR-T therapy with PD-1 knocko.


    In addition to expressing a chimeric antigen receptor (CAR) targeting CD19, gene editing was used to knock down the expression of the immune checkpoint protein PD-1, aiming to improve the persistence of antitumor activi.


    ▲Introduction of CB-010 (Image source: Caribou Biosciences official website)

    ▲Introduction of CB-010 (Image source: Caribou Biosciences official website)

    As of February 23, 2022, 6 patients had received CB-010, and 5 patients had completed the dose-limiting toxicity assessment at 28 da.


    All 4 patients who achieved complete remission at 28 days had continued remission at 3 mont.


    ▲ Results of patients treated with CB-010 (Image source: Caribou Biosciences official website)

    ▲ Results of patients treated with CB-010 (Image source: Caribou Biosciences official website)

    In terms of safety, no graft-versus-host disease was found, and one patient developed grade 1 cytokine release syndrome (CRS) and grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS), which were defined as dose-limiting toxiciti.


    Based on the positive safety and efficacy data obtained in this cohort of patients, this clinical trial will enroll patients to receive higher doses of CB-01

    "Our initial data for CB-010 are exciti.


    References:

    References:

    [1] Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Thera.


    [1] Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Thera.


    [2] CB-010 Clinical Program Upda.
    Retrieved May 12, 2022, from https://invest.
    cariboub.
    com/static-files/cd6999e4-39cc-4157-881e-06cab012fa85
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.